|
| [November 07, 2012] |
 |
IntriCon Reports 2012 Third-Quarter Results
ARDEN HILLS, Minn. --(Business Wire)--
IntriCon Corporation (NASDAQ: IIN), a designer, developer,
manufacturer and distributor of miniature and micro-miniature body-worn
devices, today announced financial results for its third quarter ended
September 30, 2012.
For the 2012 third quarter, the company reported net sales of $14.9
million, an increase of 7.4 percent from the prior-year period. IntriCon
had net income of $217,000, or $0.04 per diluted share, compared to a
net loss of $(489,000), or $(0.09) per diluted share, for the 2011 third
quarter. Included in 2012 third-quarter results was a one-time gain of
$822,000, or $0.14 per diluted share, from the previously disclosed sale
of the company's 50-percent ownership interest in Global Coils, to its
Switzerland-based joint venture partner, Audemars SA.
"There were encouraging developments across all of our businesses in the
third quarter," said Mark S. Gorder, president and chief executive
officer of IntriCon. "Professional audio posted record sales that were
up 53.4 percent over the 2011 third quarter as strong demand continued
for securities products domestically and headset products
internationally.
"On the medical front, we increased sales over the prior-year period
with our largest medical customer, Medtronic. And in hearing health, hi
HealthInnovations, a UnitedHealth Group Company, expanded its
innovative hearing aid program to more than 26 million people enrolled
in its employer-sponsored and individual health benefit plans. Hearing
health sales, though, declined 6.9 percent over the prior year,
primarily due to an expected pause in orders from hi HealthInnovations
and continued softness in the conventional hearing health market."
As a percentage of 2012 third-quarter sales, healthcare-related revenue
(hearing health and medical combined) totaled 67.7 percent (30.6 percent
hearing health and 37.1 percent medical), with professional audio
communications at 32.3 percent. This compares to 2011 healthcare-related
revenue of 77.3 percent (35.3 percent hearing health and 42.0 percent
medical), with professional audio communications at 22.7 percent.
Gross profit margins were down slightly to 21.6 percent from 22.2
percent in the prior-year third quarter. The decline was primarily due
to higher cost of goods sold, stemming from increased manufacturing
infrastructure costs in Singapore and Indonesia.
"The infrastructure in Singapore and Indonesia has positioned IntriCon
well for additional low-cost labor intensive opportunities," said
Gorder. "As we transfer select labor-intensive programs to these
locations, we believe we will be more cost competitive as a whole, and
we expect to experience margin improvement."
IntriCon reduced its operating expenses in the third quarter, despite
higher sales.
Nine-Month Results For the 2012 nine-month period, IntriCon
reported net sales of $47.3 million and net income of $377,000, or $0.06
per diluted share. This is up from 2011 net sales of $41.6 million and a
net loss of $(1.1 million), or $(0.19) per diluted share. Hearing health
sales rose 17.4 percent over the prior-year nine months, with medical
and professional audio up 4.7 percent and 24.2 percent, respectively.
Included in 2012 nine-month results was the one-time gain of $822,000,
or $0.14 per diluted share, from the Global Coils sale.
As a percentage of 2012 nine-month sales, healthcare-related revenue
(hearing health and medical combined) totaled 76.5 percent (38.8 percent
hearing health and 37.7 percent medical), with professional audio
communications at 23.5 percent. This compares to 2011 healthcare-related
revenue of 78.5 percent (37.6 percent hearing health and 40.9 percent
medical), with professional audio communications at 21.5 percent.
Gross profit margins for the 2012 nine months were 23.4 percent, up from
22.4 percent in the prior-year period, primarily due to volume
increases, partially offset by increased manufacturing infrastructure in
Singapore and Indonesia.
hi HealthInnovations According to Gorder, "As previously
disclosed, we've satisfied hi HealthInnovations' initial product
ramp-up needs for 2012. In the near-term, we expect minimal new orders;
however, we continue to be optimistic about the long-term prospects of
this program.
"We are encouraged by hi HealthInnovations' progress building
the necessary infrastructure to provide high-quality, affordable hearing
healthcare to their customers. UnitedHealthcare recently announced that
it is making hi HealthInnovations' high-tech, custom-programmed
hearing aids available at a discounted price to more than 26 million
people enrolled in its employer-sponsored and individual health benefit
plans. We believe this will drive significant growth for IntriCon in
2013, specifically in the second half of the year."
Business Update IntriCon recently introduced its new
Audion6™, a six-channel hearing aid amplifier, and the Lumen™ 1000
wireless hearing system at the 57th annual International
Congress of Hearing Aid Acousticians in Germany. Audion6 is a
feature-rich amplifier designed to fit a wide array of applications. In
addition to multiple compression channels, the amplifier has a complete
set of proven adaptive features which greatly improve the user
experience.
Lumen 1000 is a next-generation, wireless hearing system within
IntriCon's existing Lumen product family. Lumen 1000 incorporates the
company's intuitive Physiolink™ wireless technology to allow clear
communication. With flexStrem™, voiceStream™, linkStream™, and
callStream™ accessories, the device can wirelessly stream music,
television, audio or a companion's voice-making it significantly more
versatile and effective than traditional hearing devices. IntriCon also
believes this technology and functionality holds great potential in the
non-traditional hearing health market.
Within its medical business, year over year sales were down slightly in
the third quarter. Said Gorder, "We experienced a temporary slowdown in
medical growth in the third quarter. This was primarily due to order
timing and customer inventory management. We're already seeing medical
sales rebound, and we expect them to strengthen in the fourth quarter to
levels consistent with the first half of the year.
"The shift to small and lightweight, advanced body-worn medical devices
continues. Our core technology and product offerings have the proven
ability to connect patients and caregivers in non-traditional ways,
which positions us to help our customers and their patients.
Furthermore, we intend to focus more capital and resources in sales and
marketing to expand our reach to other large medical device and
healthcare companies that we are not doing business with today. "
On the cardiac front, IntriCon is delivering demo units of its two
FDA-approved wireless cardiac diagnostic monitoring devices-Centauri™
and Sirona™- to targeted customers. The company continues to anticipate
these products will generate initial revenue in the fourth quarter and
ramp-up in 2013.
Third-quarter professional audio communications sales were very strong,
up more than 50 percent from the prior-year period. The company
continues delivery on its significant contract with the Singapore
government, providing technically advanced headsets to be worn in
difficult listening environments. This contract will run through the end
of 2012. In addition, IntriCon has seen steady growth in its securities
business.
Looking Ahead Concluded Gorder, "We remain steadfast in our
goals for 2012: developing new core technologies while enhancing
existing ones; securing additional market-changing relationships with
leaders in the healthcare industry; expanding and driving efficiencies
at our international manufacturing facilities; increasing our sales and
marketing resources; and driving profitability."
Conference Call Today As previously announced, the company
will hold an investment community conference call today, Wednesday,
November 7, 2012, beginning at 4:00 p.m. CT. Mark Gorder, president and
chief executive officer, and Scott Longval, chief financial officer,
will review third-quarter performance and discuss the company's
strategies. To join the conference call, dial: 1-888-549-7880
(international 1-480-629-9643) and provide the conference identification
number 4571342 to the operator.
A replay of the conference call will be available one hour after the
call ends through 11:59 p.m. CT on Tuesday, November 13, 2012. To access
the replay, dial 1-800-406-7325 (international 1-303-590-3030) and enter
access code: 4571342.
About IntriCon Corporation Headquartered in Arden Hills,
Minn., IntriCon Corporation designs, develops and manufactures miniature
and micro-miniature body-worn devices. These advanced products help
medical, healthcare and professional communications companies meet the
rising demand for smaller, more intelligent and better connected
devices. IntriCon has facilities in the United States, Asia and Europe.
The company's common stock trades under the symbol "IIN" on the NASDAQ
Global Market. For more information about IntriCon, visit www.intricon.com.
Forward-Looking Statements Statements made in this release
and in IntriCon's other public filings and releases that are not
historical facts or that include forward-looking terminology are
"forward-looking statements" within the meaning of the Securities
Exchange Act of 1934, as amended. These forward-looking statements may
be affected by known and unknown risks, uncertainties and other factors
that are beyond IntriCon's control, and may cause IntriCon's actual
results, performance or achievements to differ materially from the
results, performance and achievements expressed or implied in the
forward-looking statements. These risks, uncertainties and other factors
are detailed from time to time in the company's filings with the
Securities and Exchange Commission, including the Annual Report on Form
10-K for the year ended December 31, 2011. The company disclaims any
intent or obligation to publicly update or revise any forward-looking
statements, regardless of whether new information becomes available,
future developments occur or otherwise.
|
|
|
|
|
IntriCon Corporation
|
|
Consolidated Condensed Statements of Operations
|
|
(in thousands, except per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
|
|
(Unaudited)
|
|
|
(Unaudited)
|
|
|
(Unaudited)
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales, net
|
|
|
$
|
14,904
|
|
|
|
$
|
13,873
|
|
|
|
$
|
47,268
|
|
|
|
$
|
41,584
|
|
|
Cost of sales
|
|
|
|
11,679
|
|
|
|
|
10,789
|
|
|
|
|
36,209
|
|
|
|
|
32,261
|
|
|
Gross profit
|
|
|
|
3,225
|
|
|
|
|
3,084
|
|
|
|
|
11,059
|
|
|
|
|
9,323
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales and marketing
|
|
|
|
734
|
|
|
|
|
734
|
|
|
|
|
2,363
|
|
|
|
|
2,422
|
|
|
General and administrative
|
|
|
|
1,504
|
|
|
|
|
1,486
|
|
|
|
|
4,744
|
|
|
|
|
4,382
|
|
|
Research and development
|
|
|
|
1,243
|
|
|
|
|
1,326
|
|
|
|
|
3,513
|
|
|
|
|
3,600
|
|
|
Total operating expenses
|
|
|
|
3,481
|
|
|
|
|
3,546
|
|
|
|
|
10,620
|
|
|
|
|
10,404
|
|
|
Operating income (loss)
|
|
|
|
(256
|
)
|
|
|
|
(462
|
)
|
|
|
|
439
|
|
|
|
|
(1,081
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
|
(210
|
)
|
|
|
|
(144
|
)
|
|
|
|
(588
|
)
|
|
|
|
(431
|
)
|
|
Equity in income (loss) of partnerships
|
|
|
|
(39
|
)
|
|
|
|
(12
|
)
|
|
|
|
(77
|
)
|
|
|
|
317
|
|
|
Gain on sale of investment in partnership
|
|
|
|
822
|
|
|
|
|
--
|
|
|
|
|
822
|
|
|
|
|
--
|
|
|
Other (loss) expense
|
|
|
|
(36
|
)
|
|
|
|
69
|
|
|
|
|
(64
|
)
|
|
|
|
32
|
|
|
Income (loss) before income taxes
|
|
|
|
281
|
|
|
|
|
(549
|
)
|
|
|
|
532
|
|
|
|
|
(1,163
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense (benefit)
|
|
|
|
64
|
|
|
|
|
(60
|
)
|
|
|
|
155
|
|
|
|
|
(90
|
)
|
|
Net income (loss)
|
|
|
$
|
217
|
|
|
|
$
|
(489
|
)
|
|
|
$
|
377
|
|
|
|
$
|
(1,073
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
$
|
0.04
|
|
|
|
$
|
(0.09
|
)
|
|
|
$
|
0.07
|
|
|
|
$
|
(0.19
|
)
|
|
Diluted
|
|
|
$
|
0.04
|
|
|
|
$
|
(0.09
|
)
|
|
|
$
|
0.06
|
|
|
|
$
|
(0.19
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Average shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
|
5,674
|
|
|
|
|
5,600
|
|
|
|
|
5,666
|
|
|
|
|
5,576
|
|
|
Diluted
|
|
|
|
5,854
|
|
|
|
|
5,600
|
|
|
|
|
5,910
|
|
|
|
|
5,576
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IntriCon Corporation
|
|
Consolidated Condensed Balance Sheets
|
|
(in thousands, except per share data)
|
|
|
|
|
|
|
September 30,
|
|
|
|
|
|
|
|
2012
|
|
|
December 31,
|
|
|
|
|
(Unaudited)
|
|
|
2011
|
|
Current assets:
|
|
|
|
|
|
|
|
Cash
|
|
|
$
|
244
|
|
|
|
$
|
119
|
|
|
Restricted cash
|
|
|
|
553
|
|
|
|
|
540
|
|
|
Accounts receivable, less allowance for doubtful accounts
|
|
|
|
8,295
|
|
|
|
|
8,545
|
|
|
Inventories
|
|
|
|
11,976
|
|
|
|
|
11,720
|
|
|
Refundable income taxes
|
|
|
|
--
|
|
|
|
|
82
|
|
|
Other current assets
|
|
|
|
1,074
|
|
|
|
|
652
|
|
|
Total current assets
|
|
|
|
22,142
|
|
|
|
|
21,658
|
|
|
|
|
|
|
|
|
|
|
Machinery and equipment
|
|
|
|
40,547
|
|
|
|
|
39,170
|
|
|
Less: Accumulated depreciation
|
|
|
|
33,563
|
|
|
|
|
32,164
|
|
|
Net machinery and equipment
|
|
|
|
6,984
|
|
|
|
|
7,006
|
|
|
|
|
|
|
|
|
|
|
Goodwill
|
|
|
|
9,709
|
|
|
|
|
9,709
|
|
|
Investment in partnerships
|
|
|
|
812
|
|
|
|
|
1,283
|
|
|
Other assets, net
|
|
|
|
1,268
|
|
|
|
|
1,074
|
|
|
Total assets
|
|
|
$
|
40,915
|
|
|
|
$
|
40,730
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
Checks written in excess of cash
|
|
|
$
|
637
|
|
|
|
$
|
396
|
|
|
Current maturities of long-term debt
|
|
|
|
3,225
|
|
|
|
|
2,883
|
|
|
Accounts payable
|
|
|
|
4,813
|
|
|
|
|
6,298
|
|
|
Accrued salaries, wages and commissions
|
|
|
|
2,134
|
|
|
|
|
1,617
|
|
|
Deferred gain
|
|
|
|
110
|
|
|
|
|
110
|
|
|
Partnership payable
|
|
|
|
240
|
|
|
|
|
240
|
|
|
Other accrued liabilities
|
|
|
|
2,422
|
|
|
|
|
1,907
|
|
|
Total current liabilities
|
|
|
|
13,581
|
|
|
|
|
13,451
|
|
|
|
|
|
|
|
|
|
|
Long-term debt, less current maturities
|
|
|
|
7,530
|
|
|
|
|
8,217
|
|
|
Other postretirement benefit obligations
|
|
|
|
670
|
|
|
|
|
685
|
|
|
Accrued pension liabilities
|
|
|
|
415
|
|
|
|
|
431
|
|
|
Deferred gain
|
|
|
|
312
|
|
|
|
|
385
|
|
|
Other long-term liabilities
|
|
|
|
139
|
|
|
|
|
115
|
|
|
Total liabilities
|
|
|
|
22,647
|
|
|
|
|
23,284
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders' equity:
|
|
|
|
|
|
|
|
Common stock, $1.00 par value per share; 20,000 shares authorized;
5,680 and 5,646 shares issued outstanding at September 30, 2012 and
December 31, 2011, respectively
|
|
|
|
5,680
|
|
|
|
|
5,646
|
|
|
Additional paid-in capital
|
|
|
|
15,669
|
|
|
|
|
15,259
|
|
|
Accumulated deficit
|
|
|
|
(2,692
|
)
|
|
|
|
(3,069
|
)
|
|
Accumulated other comprehensive loss
|
|
|
|
(389
|
)
|
|
|
|
(390
|
)
|
|
Total shareholders' equity
|
|
|
|
18,268
|
|
|
|
|
17,446
|
|
|
Total liabilities and shareholders' equity
|
|
|
$
|
40,915
|
|
|
|
$
|
40,730
|
|

[ Back To asia.tmcnet.com's Homepage 's Homepage ]
|